Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients | Zendy

Rajbharan Yadav | Zendy; Phillip J. Bergen | Zendy; Kate E. Rogers | Zendy; Carl M. J. Kirkpatrick | Zendy; Steven C. Wallis | Zendy; Yuling Huang | Zendy; Jürgen B. Bulitta | Zendy; David L. Paterson | Zendy; Jeffrey Lipman | Zendy; Roger L. Nation | Zendy; Jason A. Roberts | Zendy; Cornelia B. Landersdorfer | Zendy

Open Access

Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients

Author(s) -

Rajbharan Yadav,

Phillip J. Bergen,

Kate E. Rogers,

Carl M. J. Kirkpatrick,

Steven C. Wallis,

Yuling Huang,

Jürgen B. Bulitta,

David L. Paterson,

Jeffrey Lipman,

Roger L. Nation,

Jason A. Roberts,

Cornelia B. Landersdorfer

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01679-19

Subject(s) - meropenem , tobramycin , carbapenem , pseudomonas aeruginosa , pharmacokinetics , liter , medicine , antibiotics , antibacterial agent , renal function , microbiology and biotechnology , pharmacology , biology , gentamicin , bacteria , antibiotic resistance , genetics

Augmented renal clearance (ARC) is common in critically ill patients and is associated with subtherapeutic concentrations of renally eliminated antibiotics. We investigated the impact of ARC on bacterial killing and resistance amplification for meropenem and tobramycin regimens in monotherapy and combination. Two carbapenem-resistantPseudomonas aeruginosa isolates were studied in static-concentration time-kill studies. One isolate was examined comprehensively in a 7-day hollow-fiber infection model (HFIM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research